Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.52 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | PLG | P00747 | 1/20 | 0.30 |
| ▸ | PLAT | P00750 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.30 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.30 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.30 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.30 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18031722 | 0.88 | NCF1 (0.43) | NCF1CXCR4HTT | |
| SCHEMBL15706251 | 0.82 | THRA (0.34) | NCF1CHRM4 | |
| SCHEMBL5889468 | 0.80 | NCF1 (0.45) | NCF1CXCR4HTT | |
| SCHEMBL16827090 | 0.80 | NCF1 (0.45) | NCF1CXCR4HTTPLGPLAT | |
| SCHEMBL12233081 | 0.80 | GNAO1 (0.33) | CHRM4 | |
| SCHEMBL2583587 | 0.78 | NCF1 (0.46) | NCF1CXCR4PLGPLATLMNA | |
| SCHEMBL14006353 | 0.78 | CHRM4 (0.34) | CHRM4 | |
| SCHEMBL20314497 | 0.78 | CHRM4 (0.36) | CHRM4 | |
| SCHEMBL1572854 | 0.78 | POLB (0.34) | CHRM4 | |
| SCHEMBL6262348 | 0.77 | NCF1 (0.42) | NCF1CXCR4HTTPLGPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160046625-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC (US) | 2016-02-18 | — | — | US | disclosed |
| US-20150306086-A1 | MODULATING CERTAIN TYROSINE KINASES | TESARO, INC. | 2015-10-29 | — | — | US | disclosed |
| US-9115127-B2 | Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase | AMGEN INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20130217668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-7012080-B2 | Imidazopyridine compounds as 5-HT4 receptor agonists | PFIZER INC. (US) | 2006-03-14 | — | — | US | disclosed |
| US-20040122043-A1 | Imidazopyridine compounds as 5-HT4 receptor agonists | PFIZER INC | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046625-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | BCL6, DCK, FLI1 | NCF1 1417/4885CXCR4 4307/4885HTT 4614/4885 |
| US-20150306086-A1 | MODULATING CERTAIN TYROSINE KINASES | ABL1, LCK, FLT3 | NCF1 565/4885CXCR4 1407/4885HTT 2980/4885 |
| US-20130217668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | BCL6, DCK, FLI1 | NCF1 1417/4885CXCR4 4307/4885HTT 4614/4885 |
| US-20040122043-A1 | Imidazopyridine compounds as 5-HT4 receptor agonists | HTR4, GPR4, HRH4 | NCF1 2784/4885CXCR4 346/4885HTT 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.